CAS NO: | 1044758-60-2 |
包装 | 价格(元) |
1mg | 电议 |
5mg | 电议 |
10mg | 电议 |
50mg | 电议 |
生物活性 | Etrolizumab (rhuMAb Beta7) is a gut-selective, anti-β7integrinmonoclonal antibody. Etrolizumab is specific targeting of the β7 subunit ofα4β7and αEβ7 integrins withKivalues of 18 nM and 1800 pM for Humanα4β7and Human αEβ7-293, respectively. Etrolizumab can be used in research of inflammatory bowel disease (IBD)[1][2]. | ||||||||||||||||
IC50& Target[1] |
| ||||||||||||||||
体外研究 (In Vitro) | Etrolizumab (rhuMAb Beta7) binds the β7 subunit of both α4β7 and αEβ7 integrins with high affinity, with Kdvalues of 18 nM, 1800 pM, 181 pM, 116 pM, 57 pM, 31.7 pM, and 25.7 pM for Human α4β7, Human αEβ7-293, Mouse α4β7-38C13, Human α4β7-293, Rabbit PBLs, Human PBLs, and Cyno PBLs, respectively[1]. | ||||||||||||||||
体内研究 (In Vivo) | Etrolizumab (rhuMAb Beta7; 5 mg/kg; i.v.; once; normal female BALB/c mice) decreases β7 integrins on T lymphocytes[2].
| ||||||||||||||||
Clinical Trial | |||||||||||||||||
性状 | Liquid | ||||||||||||||||
CAS 号 | 1044758-60-2 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |